This content is machine translated Breast Cancer New options in advanced breast cancer While new lecture formats had to be established due to the Corona pandemic, substantial progress in research around cancer therapies remained constant, as evidenced by study results presented at EHA.…
View Post 4 min This content is machine translated Non-resectable melanoma New triple therapy improves progression-free survival Both protein kinase inhibitors and ipilimumab/nivolumab combined have better efficacy than their respective monotherapies in patients with non-resectable melanoma. This has been known for some time. An interesting new approach…
View Post 3 min This content is machine translated Ovarian Cancer Improved PFS argues for maintenance therapy with PARP inhibitor More women die from ovarian cancer than from any other tumor – mainly because it is usually detected very late. PARP inhibitors have been developed for the treatment of recurrent…
View Post 9 min This content is machine translated Epithelial ovarian carcinoma Newer therapeutic concepts with longer disease-free survival Ovarian cancer is usually diagnosed at an advanced stage and has an unfavorable prognosis. Maximal cytoreductive surgery, if possible, is the first priority therapeutically and prognostically, followed by platinum-containing chemotherapy.…
View Post 7 min This content is machine translated Metastatic non-small cell lung cancer Drug therapy 2014 Determination of EGFR mutational status and EML-ALK translocations in patients with metastatic adenocarcinoma has therapeutic implications and should be requested at diagnosis. Maintenance treatment with pemetrexed in patients with non-squamous…
View Post 10 min This content is machine translated Treatment of epithelial ovarian cancer. Slow but steady progress Epithelial ovarian carcinoma is a heterogeneous group of carcinomas that have different etiology, genetics, and thus biological prognosis. In advanced stages (IIB-IV), the standard therapy remains maximal cytoreductive therapy, weighing…
